Dr. Dale Bredesen, MD

Elle Russ chats with Dr. Dale Bredesen, MD – he received his undergraduate degree from Caltech and his medical degree from Duke.  He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner.  He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging.  In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease.  He and his group developed a new approach to the treatment of Alzheimer’s disease, and this approach led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014, 2016, and 2018.  Dr. Bredesen is the author of the New York Times best seller, The End of Alzheimer’s, and the newly released, The End of Alzheimer’s Program.

SELECTED LINKS

Dr. Bredesen WEBSITE

Connect with Show Host ELLE RUSS

Get the Primal Blueprint Podcast

  • Download Episode #498 HERE right click to “Save As”)
  • Subscribe to The Primal Blueprint Podcast on Apple Podcasts here and on Stitcher here
  • Subscribe to the RSS feed here

Do you have a question you would like answered on a future Primal Blueprint Podcast?… email us!

Leave a Reply

Your email address will not be published.